Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.

Garceau D, Chauret N.

Pulm Pharmacol Ther. 2019 Jun;56:56-62. doi: 10.1016/j.pupt.2019.03.007. Epub 2019 Mar 20.

PMID:
30902655
2.

Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.

Li P, Dorsch W, Lauffer DJ, Bilimoria D, Chauret N, Court JJ, Das SK, Denis F, Mani N, Nanthakumar S, Nicolas O, Rao BG, Ronkin S, Selliah S, Shawgo RS, Stearns R, Tang Q, Waal ND, Green J.

ACS Med Chem Lett. 2017 Jan 31;8(2):251-255. doi: 10.1021/acsmedchemlett.6b00479. eCollection 2017 Feb 9.

3.

Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.

Court JJ, Poisson C, Ardzinski A, Bilimoria D, Chan L, Chandupatla K, Chauret N, Collier PN, Das SK, Denis F, Dorsch W, Iyer G, Lauffer D, L'Heureux L, Li P, Luisi BS, Mani N, Nanthakumar S, Nicolas O, Rao BG, Ronkin S, Selliah S, Shawgo RS, Tang Q, Waal ND, Yannopoulos CG, Green J.

J Med Chem. 2016 Jul 14;59(13):6293-302. doi: 10.1021/acs.jmedchem.6b00541. Epub 2016 Jul 1.

PMID:
27366941
4.

In Vitro and In Vivo Mechanistic Studies toward Understanding the Role of 1-Aminobenzotriazole in Rat Drug-Drug Interactions.

Boily MO, Chauret N, Laterreur J, Leblond FA, Boudreau C, Duquet MC, Lévesque JF, Ste-Marie L, Pichette V.

Drug Metab Dispos. 2015 Dec;43(12):1960-5. doi: 10.1124/dmd.115.066357. Epub 2015 Oct 5.

PMID:
26438628
5.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.

Giroux S, Bilimoria D, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Henderson JA, L'Heureux L, Mani N, Morris M, Nicolas O, Reddy TJ, Selliah S, Shawgo RS, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):940-3. doi: 10.1016/j.bmcl.2014.12.044. Epub 2014 Dec 29.

PMID:
25597006
6.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers.

Giroux S, Bilimoria D, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Henderson JA, L'Heureux L, Mani N, Morris M, Nicolas O, Reddy TJ, Selliah S, Shawgo RS, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):936-9. doi: 10.1016/j.bmcl.2014.12.046. Epub 2014 Dec 30.

PMID:
25595681
7.

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.

Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Dietrich E, Denis F, Ewing N, Falardeau G, Giroux S, Grey R Jr, L'Heureux L, Liu B, Mani N, Morris M, Nicolas O, Pereira OZ, Poisson C, Govinda Rao B, Reddy TJ, Selliah S, Shawgo RS, Vaillancourt L, Wang J, Yannopoulos CG, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):944-7. doi: 10.1016/j.bmcl.2014.12.045. Epub 2014 Dec 20.

PMID:
25577041
8.

Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.

Henderson JA, Bilimoria D, Bubenik M, Cadilhac C, Cottrell KM, Denis F, Dietrich E, Ewing N, Falardeau G, Giroux S, L'Heureux L, Liu B, Mani N, Morris M, Nicolas O, Pereira OZ, Poisson C, Reddy TJ, Selliah S, Shawgo RS, Vaillancourt L, Wang J, Xu J, Chauret N, Berlioz-Seux F, Chan LC, Das SK, Grillot AL, Bennani YL, Maxwell JP.

Bioorg Med Chem Lett. 2015 Feb 15;25(4):948-51. doi: 10.1016/j.bmcl.2014.12.042. Epub 2014 Dec 22.

PMID:
25577039
9.

Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors.

Giroux S, Xu J, Reddy TJ, Morris M, Cottrell KM, Cadilhac C, Henderson JA, Nicolas O, Bilimoria D, Denis F, Mani N, Ewing N, Shawgo R, L'Heureux L, Selliah S, Chan L, Chauret N, Berlioz-Seux F, Namchuk MN, Grillot AL, Bennani YL, Das SK, Maxwell JP.

ACS Med Chem Lett. 2013 Jan 27;5(3):240-3. doi: 10.1021/ml300461f. eCollection 2014 Mar 13.

10.

Pharmacokinetics and metabolism in rats, dogs, and monkeys of the cathepsin k inhibitor odanacatib: demethylation of a methylsulfonyl moiety as a major metabolic pathway.

Kassahun K, Black WC, Nicoll-Griffith D, McIntosh I, Chauret N, Day S, Rosenberg E, Koeplinger K.

Drug Metab Dispos. 2011 Jun;39(6):1079-87. doi: 10.1124/dmd.110.037184. Epub 2011 Mar 21.

PMID:
21422190
11.

Difluoroethylamines as an amide isostere in inhibitors of cathepsin K.

Isabel E, Mellon C, Boyd MJ, Chauret N, Deschênes D, Desmarais S, Falgueyret JP, Gauthier JY, Khougaz K, Lau CK, Léger S, Levorse DA, Li CS, Massé F, Percival MD, Roy B, Scheigetz J, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):920-3. doi: 10.1016/j.bmcl.2010.12.070. Epub 2010 Dec 19.

PMID:
21232956
12.

The discovery of MK-0674, an orally bioavailable cathepsin K inhibitor.

Isabel E, Bateman KP, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Gauthier JY, Lamontagne S, Lau CK, Léger S, LeRiche T, Lévesque JF, Li CS, Massé F, McKay DJ, Mellon C, Nicoll-Griffith DA, Oballa RM, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2010 Feb 1;20(3):887-92. doi: 10.1016/j.bmcl.2009.12.083. Epub 2009 Dec 28.

PMID:
20061146
13.

Alkyl-bridged substituted 8-arylquinolines as highly potent PDE IV inhibitors.

Lacombe P, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Gallant M, Girard Y, Huang Z, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini JA, Masson P, Nicholson DW, Nicoll-Griffith DA, Salem M, Styhler A, Young RN.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5266-9. doi: 10.1016/j.bmcl.2009.03.105. Epub 2009 Mar 26.

PMID:
19640717
14.

Evaluation of VCH-759 monotherapy in hepatitis C infection.

Cooper C, Lawitz EJ, Ghali P, Rodriguez-Torres M, Anderson FH, Lee SS, Bédard J, Chauret N, Thibert R, Boivin I, Nicolas O, Proulx L.

J Hepatol. 2009 Jul;51(1):39-46. doi: 10.1016/j.jhep.2009.03.015. Epub 2009 Apr 23.

PMID:
19446909
15.

Investigation of ketone warheads as alternatives to the nitrile for preparation of potent and selective cathepsin K inhibitors.

Boyd MJ, Crane SN, Robichaud J, Scheigetz J, Black WC, Chauret N, Wang Q, Massé F, Oballa RM.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):675-9. doi: 10.1016/j.bmcl.2008.12.053. Epub 2008 Dec 24.

PMID:
19117756
16.

Selective isolation of in vitro phase II conjugates using a lipophilic anionic exchange solid phase extraction method.

Gagné S, Laterreur J, Mahrouche L, Sørensen D, Gauthier JY, Truong VL, Chauret N, Lévesque JF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Mar 1;863(2):242-8. doi: 10.1016/j.jchromb.2008.01.032. Epub 2008 Jan 30.

PMID:
18262477
17.

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong LT, Falgueyret JP, Kimmel DB, Lamontagne S, Léger S, LeRiche T, Li CS, Massé F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Thérien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R, Black WC.

Bioorg Med Chem Lett. 2008 Feb 1;18(3):923-8. doi: 10.1016/j.bmcl.2007.12.047. Epub 2008 Jan 15.

PMID:
18226527
18.

Design, synthesis, and biological evaluation of 8-biarylquinolines: a novel class of PDE4 inhibitors.

Gallant M, Chauret N, Claveau D, Day S, Deschênes D, Dubé D, Huang Z, Lacombe P, Laliberté F, Lévesque JF, Liu S, Macdonald D, Mancini J, Masson P, Mastracchio A, Nicholson D, Nicoll-Griffith DA, Perrier H, Salem M, Styhler A, Young RN, Girard Y.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1407-12. doi: 10.1016/j.bmcl.2008.01.004. Epub 2008 Jan 8.

PMID:
18207397
19.

Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

Lévesque JF, Day SH, Chauret N, Seto C, Trimble L, Bateman KP, Silva JM, Berthelette C, Lachance N, Boyd M, Li L, Sturino CF, Wang Z, Zamboni R, Young RN, Nicoll-Griffith DA.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3038-43. Epub 2007 Mar 23.

PMID:
17418572
20.

Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

Sturino CF, O'Neill G, Lachance N, Boyd M, Berthelette C, Labelle M, Li L, Roy B, Scheigetz J, Tsou N, Aubin Y, Bateman KP, Chauret N, Day SH, Lévesque JF, Seto C, Silva JH, Trimble LA, Carriere MC, Denis D, Greig G, Kargman S, Lamontagne S, Mathieu MC, Sawyer N, Slipetz D, Abraham WM, Jones T, McAuliffe M, Piechuta H, Nicoll-Griffith DA, Wang Z, Zamboni R, Young RN, Metters KM.

J Med Chem. 2007 Feb 22;50(4):794-806.

PMID:
17300164
21.

A generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds.

Oballa RM, Truchon JF, Bayly CI, Chauret N, Day S, Crane S, Berthelette C.

Bioorg Med Chem Lett. 2007 Feb 15;17(4):998-1002. Epub 2006 Nov 17.

PMID:
17157022
22.

In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.

Nicoll-Griffith DA, Seto C, Aubin Y, Lévesque JF, Chauret N, Day S, Silva JM, Trimble LA, Truchon JF, Berthelette C, Lachance N, Wang Z, Sturino C, Braun M, Zamboni R, Young RN.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):301-4. Epub 2006 Oct 25.

PMID:
17095220
23.

Comparison between two classes of selective EP(3) antagonists and their biological activities.

Belley M, Chan CC, Gareau Y, Gallant M, Juteau H, Houde K, Lachance N, Labelle M, Sawyer N, Tremblay N, Lamontagne S, Carrière MC, Denis D, Greig GM, Slipetz D, Gordon R, Chauret N, Li C, Zamboni RJ, Metters KM.

Bioorg Med Chem Lett. 2006 Nov 1;16(21):5639-42. Epub 2006 Aug 22.

PMID:
16931013
24.

Interspecies in vitro metabolism of the phosphodiesterase-4 (PDE4) inhibitor L-454,560.

Bateman KP, Trimble L, Chauret N, Silva J, Day S, Macdonald D, Dube D, Gallant M, Mastracchio A, Perrier H, Girard Y, Nicoll-Griffith D.

J Mass Spectrom. 2006 Jun;41(6):771-80.

PMID:
16705670
25.

Substituted coumarins as potent 5-lipoxygenase inhibitors.

Grimm EL, Brideau C, Chauret N, Chan CC, Delorme D, Ducharme Y, Ethier D, Falgueyret JP, Friesen RW, Guay J, Hamel P, Riendeau D, Soucy-Breau C, Tagari P, Girard Y.

Bioorg Med Chem Lett. 2006 May 1;16(9):2528-31. Epub 2006 Feb 7.

PMID:
16464579
26.

Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K.

Crane SN, Black WC, Palmer JT, Davis DE, Setti E, Robichaud J, Paquet J, Oballa RM, Bayly CI, McKay DJ, Somoza JR, Chauret N, Seto C, Scheigetz J, Wesolowski G, Massé F, Desmarais S, Ouellet M.

J Med Chem. 2006 Feb 9;49(3):1066-79.

PMID:
16451072
27.

Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

Macdonald D, Mastracchio A, Perrier H, Dubé D, Gallant M, Lacombe P, Deschênes D, Roy B, Scheigetz J, Bateman K, Li C, Trimble LA, Day S, Chauret N, Nicoll-Griffith DA, Silva JM, Huang Z, Laliberté F, Liu S, Ethier D, Pon D, Muise E, Boulet L, Chan CC, Styhler A, Charleson S, Mancini J, Masson P, Claveau D, Nicholson D, Turner M, Young RN, Girard Y.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5241-6. Epub 2005 Sep 15.

PMID:
16168647
28.

A strategy for identification of drug metabolites from dried blood spots using triple-quadrupole/linear ion trap hybrid mass spectrometry.

Mauriala T, Chauret N, Oballa R, Nicoll-Griffith DA, Bateman KP.

Rapid Commun Mass Spectrom. 2005;19(14):1984-92.

PMID:
15954171
29.
30.

Discovery, biosynthesis, and structure elucidation of new metabolites of norandrostenedione using in vitro systems.

Lévesque JF, Gaudreault M, Aubin Y, Chauret N.

Steroids. 2005 Apr;70(4):305-17.

PMID:
15784285
31.

Structure-activity relationship studies on ortho-substituted cinnamic acids, a new class of selective EP(3) antagonists.

Belley M, Gallant M, Roy B, Houde K, Lachance N, Labelle M, Trimble LA, Chauret N, Li C, Sawyer N, Tremblay N, Lamontagne S, Carrière MC, Denis D, Greig GM, Slipetz D, Metters KM, Gordon R, Chan CC, Zamboni RJ.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):527-30.

PMID:
15664806
32.

Use of a benzyloxy-substituted lactone cyclooxygenase-2 inhibitor as a selective fluorescent probe for CYP3A activity in primary cultured rat and human hepatocytes.

Nicoll-Griffith DA, Chauret N, Houle R, Day SH, D'Antoni M, Silva JM.

Drug Metab Dispos. 2004 Dec;32(12):1509-15.

PMID:
15550722
33.

Detection of covalent adducts to cytochrome P450 3A4 using liquid chromatography mass spectrometry.

Bateman KP, Baker J, Wilke M, Lee J, Leriche T, Seto C, Day S, Chauret N, Ouellet M, Nicoll-Griffith DA.

Chem Res Toxicol. 2004 Oct;17(10):1356-61.

PMID:
15487896
34.

Discovery of a potent and selective agonist of the prostaglandin EP4 receptor.

Billot X, Chateauneuf A, Chauret N, Denis D, Greig G, Mathieu MC, Metters KM, Slipetz DM, Young RN.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1129-32.

PMID:
12643927
35.

Hypoxia-induced down-regulation of CYP1A1/1A2 and up-regulation of CYP3A6 involves serum mediators.

Fradette C, Bleau AM, Pichette V, Chauret N, Du Souich P.

Br J Pharmacol. 2002 Nov;137(6):881-91.

36.

Discovery of a potent and selective COX-2 inhibitor in the alkoxy lactone series with optimized metabolic profile.

Leblanc Y, Roy P, Wang Z, Li CS, Chauret N, Nicoll-Griffith DA, Silva JM, Aubin Y, Yergey JA, Chan CC, Riendeau D, Brideau C, Gordon R, Xu L, Webb J, Visco DM, Prasit P.

Bioorg Med Chem Lett. 2002 Nov 18;12(22):3317-20.

PMID:
12392741
37.

Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective.

Lévesque JF, Gaudreault M, Houle R, Chauret N.

J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Nov 15;780(1):145-53. Erratum in: J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Apr 25;787(2):427.

PMID:
12383490
38.

Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.

Frenette R, Blouin M, Brideau C, Chauret N, Ducharme Y, Friesen RW, Hamel P, Jones TR, Laliberté F, Li C, Masson P, McAuliffe M, Girard Y.

Bioorg Med Chem Lett. 2002 Oct 21;12(20):3009-13.

PMID:
12270195
39.

Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.

Guengerich FP, Miller GP, Hanna IH, Martin MV, Léger S, Black C, Chauret N, Silva JM, Trimble LA, Yergey JA, Nicoll-Griffith DA.

Biochemistry. 2002 Sep 10;41(36):11025-34.

PMID:
12206675
40.

Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding.

Chauret N, Guay D, Li C, Day S, Silva J, Blouin M, Ducharme Y, Yergey JA, Nicoll-Griffith DA.

Bioorg Med Chem Lett. 2002 Aug 19;12(16):2149-52.

PMID:
12127525
41.

Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.

Guay D, Hamel P, Blouin M, Brideau C, Chan CC, Chauret N, Ducharme Y, Huang Z, Girard M, Jones TR, Laliberté F, Masson P, McAuliffe M, Piechuta H, Silva J, Young RN, Girard Y.

Bioorg Med Chem Lett. 2002 Jun 3;12(11):1457-61.

PMID:
12031319
42.

The use of 3-[2-(N,N-diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a specific CYP2D6 probe in human liver microsomes.

Chauret N, Dobbs B, Lackman RL, Bateman K, Nicoll-Griffith DA, Stresser DM, Ackermann JM, Turner SD, Miller VP, Crespi CL.

Drug Metab Dispos. 2001 Sep;29(9):1196-200.

PMID:
11502727
43.

In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).

Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1059-62.

PMID:
11327589
44.

In vitro metabolism of the COX-2 inhibitor DFU, including a novel glutathione adduct rearomatization.

Yergey JA, Trimble LA, Silva J, Chauret N, Li C, Therien M, Grimm E, Nicoll-Griffith DA.

Drug Metab Dispos. 2001 May;29(5):638-44.

PMID:
11302928
45.

Investigation of the in vitro metabolism profile of a phosphodiesterase-IV inhibitor, CDP-840: leading to structural optimization.

Li C, Chauret N, Trimble LA, Nicoll-Griffith DA, Silva JM, MacDonald D, Perrier H, Yergey JA, Parton T, Alexander RP, Warrellow GJ.

Drug Metab Dispos. 2001 Mar;29(3):232-41.

PMID:
11181489
46.

Application of rat hepatocyte culture to predict in vivo metabolic auto-induction: studies with DFP, a cyclooxygenase-2 inhibitor.

Nicoll-Griffith DA, Silva JM, Chauret N, Day S, Leblanc Y, Roy P, Yergey JA, Dixit R, Patrick D.

Drug Metab Dispos. 2001 Feb;29(2):159-65.

PMID:
11159806
47.

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx).

Nicoll-Griffith DA, Yergey JA, Trimble LA, Silva JM, Li C, Chauret N, Gauthier JY, Grimm E, Léger S, Roy P, Thérien M, Wang Z, Prasit P, Zamboni R, Young RN, Brideau C, Chan CC, Mancini J, Riendeau D.

Bioorg Med Chem Lett. 2000 Dec 4;10(23):2683-6.

PMID:
11128651
48.

Description of a 96-well plate assay to measure cytochrome P4503A inhibition in human liver microsomes using a selective fluorescent probe.

Chauret N, Tremblay N, Lackman RL, Gauthier JY, Silva JM, Marois J, Yergey JA, Nicoll-Griffith DA.

Anal Biochem. 1999 Dec 15;276(2):215-26.

PMID:
10603245
49.

2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors.

Black WC, Brideau C, Chan CC, Charleson S, Chauret N, Claveau D, Ethier D, Gordon R, Greig G, Guay J, Hughes G, Jolicoeur P, Leblanc Y, Nicoll-Griffith D, Ouimet N, Riendeau D, Visco D, Wang Z, Xu L, Prasit P.

J Med Chem. 1999 Apr 8;42(7):1274-81.

PMID:
10197970
50.

Effect of common organic solvents on in vitro cytochrome P450-mediated metabolic activities in human liver microsomes.

Chauret N, Gauthier A, Nicoll-Griffith DA.

Drug Metab Dispos. 1998 Jan;26(1):1-4.

PMID:
9443844

Supplemental Content

Loading ...
Support Center